Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.75% Market Closed
Market Cap: 3.6B USD

Axonics Inc
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Axonics Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Axonics Inc
NASDAQ:AXNX
Net Issuance of Common Stock
$3.6m
CAGR 3-Years
-74%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Net Issuance of Common Stock
$290m
CAGR 3-Years
32%
CAGR 5-Years
-32%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Net Issuance of Common Stock
-$490m
CAGR 3-Years
50%
CAGR 5-Years
0%
CAGR 10-Years
6%
IDEXX Laboratories Inc
NASDAQ:IDXX
Net Issuance of Common Stock
-$1.1B
CAGR 3-Years
-6%
CAGR 5-Years
-33%
CAGR 10-Years
-10%
Intuitive Surgical Inc
NASDAQ:ISRG
Net Issuance of Common Stock
-$1.8B
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Axonics Inc
Glance View

Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.

AXNX Intrinsic Value
36.64 USD
Overvaluation 48%
Intrinsic Value
Price

See Also

What is Axonics Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
3.6m USD

Based on the financial report for Sep 30, 2024, Axonics Inc's Net Issuance of Common Stock amounts to 3.6m USD.

What is Axonics Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-52%

Over the last year, the Net Issuance of Common Stock growth was -6%. The average annual Net Issuance of Common Stock growth rates for Axonics Inc have been -74% over the past three years , -52% over the past five years .

Back to Top